Vismodegib - Roche

Drug Profile

Vismodegib - Roche

Alternative Names: Erivedge; GDC-0449; R 3616; RG 3616

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curis
  • Developer Centre Hospitalier Univeristaire De Lille; Clinica Universidad de Navarra; Erasmus Hospital; Genentech; National Cancer Institute (USA); Roche
  • Class Antineoplastics; Benzamides; Small molecules; Sulfones
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Basal cell nevus syndrome; Breast cancer; Chondrosarcoma; Gastric cancer; Medulloblastoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Graft-versus-host disease
  • Discontinued Acute myeloid leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Glioblastoma; Idiopathic pulmonary fibrosis; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 21 May 2018 Curis has patent protection for vismodegib in USA
  • 09 Dec 2017 Adverse events data from a phase Ib trial in Myelofibrosis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 23 Oct 2017 Discontinued - Phase-I/II for Myelofibrosis (Combination therapy) in USA, Canada, Italy, Germany (PO) (Roche pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top